Minerva Neurosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held on December 5, 2024. Minerva Neurosciences, Inc. (Nasdaq: NERV) is a Delaware corporation focused on neuroscience therapeutics.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance voting results.
Material Changes and Voting Results
Three proposals were submitted to stockholders, all of which were approved:
- Proposal 1 (Election of Directors): Two nominees were elected to the Board of Directors until the 2027 annual meeting.
- Hans Peter Hasler: 3,384,409 votes For; 353,053 votes Withheld; 1,624,748 Broker Non-Votes.
- Dr. Remy Luthringer: 3,705,617 votes For; 31,845 votes Withheld; 1,624,748 Broker Non-Votes.
- Proposal 2 (Advisory Executive Compensation): Stockholders approved the compensation of Named Executive Officers.
- Votes: 3,631,040 For; 101,614 Against; 4,808 Abstain; 1,624,748 Broker Non-Votes.
- Proposal 3 (Ratification of Auditors): Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes: 5,134,745 For; 160,496 Against; 66,969 Abstain; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new Board composition effective until the 2027 annual meeting.
- Verification of the significant number of Broker Non-Votes (1,624,748) on director elections and executive compensation.
- Confirmation that Deloitte & Touche LLP will serve as the auditor for the fiscal year ending December 31, 2024.